Dewpoint Therapeutics Revenue and Competitors

Boston, MA USA

Location

$287M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Dewpoint Therapeutics's estimated annual revenue is currently $34.7M per year.(i)
  • Dewpoint Therapeutics's estimated revenue per employee is $193,750
  • Dewpoint Therapeutics's total funding is $287M.

Employee Data

  • Dewpoint Therapeutics has 179 Employees.(i)
  • Dewpoint Therapeutics grew their employee count by -2% last year.

Dewpoint Therapeutics's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
SVPReveal Email/Phone
3
VP, Head R&D Strategic Planning and OperationsReveal Email/Phone
4
SVP | Head Digital and Technology Platforms | Executive Leadership TeamReveal Email/Phone
5
VP, Research and DevelopmentReveal Email/Phone
6
VP, Head Neurological & Rare DiseasesReveal Email/Phone
7
Head Discovery PlatformReveal Email/Phone
8
VP, Head Business DevelopmentReveal Email/Phone
9
SVP, Head Preclinical Development & Translational MedicineReveal Email/Phone
10
VP, Data Science and Data EngineeringReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M20%N/AN/A
#3
$5.1M336%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.4M353%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is Dewpoint Therapeutics?

Dewpoint Therapeutics is the first company founded to apply the emerging discipline of biomolecular condensates to drug discovery. Dewpoint believes that a vast range of conditions have pathways that are regulated by condensates or arise from the dysfunction of condensates ᅢᄁ¬ツᆲ¬タン including cancer, neurodegeneration, and metabolic disease. Dewpoint scientists are working in Boston, MA, and Dresden, Germany, to translate condensate biology into treatments for the toughest diseases.

keywords:N/A

$287M

Total Funding

179

Number of Employees

$34.7M

Revenue (est)

-2%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Dewpoint Therapeutics News

2022-04-17 - Recognized drug development leader to give Vera Fay ...

... and has successfully attracted investors, including raising $11 million for Trek Therapeutics and $77 million for Dewpoint Therapeutics.

2021-01-06 - Dewpoint Announces Collaboration with Pfizer to Develop Potential Therapies for a Rare Form of Muscular Dystrophy

BOSTON, Jan. 6, 2021 /PRNewswire/ -- Dewpoint Therapeutics, the biomolecular condensates company, today announced a new research collaboration with Pfizer (NYSE: PFE) for the development of potential therapeutics for the treatment of myotonic dystrophy type 1, DM1, a rare genetic disorder and ...

2020-09-29 - Dewpoint Therapeutics Raises $77M Series B Financing to Advance the Development of Drugs That Target Biomolecular Condensates

BOSTON, Sept. 29, 2020 /PRNewswire/ -- Dewpoint Therapeutics, the biomolecular condensates company, today announced it has raised $77 million in a Series B financing. The round was led by ARCH Venture Partners, with participation from new investors Maverick Ventures and Bellco Capital, and exi ...

2020-09-29 - Dewpoint Therapeutics to put 'pedal to the metal' with $77M round

Dewpoint Therapeutics was founded because “the pharma industry has kind of been fighting with one arm behind its back,” the company's CEO Amir Nashat said, citing his colleague Mark Murcko. Sponsored by Agilent Technologies How would you like to win free bench space at Lab Central for one scie ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$28.6M17933%N/A
#2
$63.6M179N/AN/A
#3
$35.6M1808%N/A
#4
$49.5M18020%N/A
#5
$41.6M180-29%N/A